FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
- 1	hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or	Secti	on 30(h)	of the	Investme	nt Co	mpany Act	of 194	0							
Name and Address of Reporting Person* Mai Xiaoying						2. Issuer Name and Ticker or Trading Symbol Twist Bioscience Corp [TWST]								(Ch	eck all applic	cable) or	g Person(s) to Iss		wner	
	(First) (Middle) TWIST BIOSCIENCE CORPORATION MISSION BAY BOULEVARD SOUTH						3. Date of Earliest Transaction (Month/Day/Year) 02/07/2022								officer below)	(give title	Other (s below)		specify	
(Street) SAN FRANCE	CA 94158					4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	ole I - Non	-Deriv	/ativ	e Se	curities	s Ac	quired	Dis	posed o	f, or	Bene	ficial	y Owned					
Date				Date	e nth/Day/Year) i		2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.		Disposed	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			Benefici	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
		Code	v	Amount					ınt (A) or P		Price	Transact	tion(s)			(Instr. 4)				
Common Stock 02/						7/2022					13,539	9 ⁽¹⁾ A		\$0	13	13,539		D		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		d Date,			s, warrants				able and	or Benefici ble securities 7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)		mount	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	e s ully	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				-	Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	OI N Oi	umber		(1130.4)				
Director Stock Option (right to buy)	\$60.33	02/07/2022			A		10,588		(1)	()7/22/2029	Comr		0,588	\$0	10,588	3	D		
Director Stock Option (right to buy)	\$60.33	02/07/2022			A		11,297		(1)		02/03/2030	Comr Stoo		1,297	\$0	11,297	7	D		
Director Stock Option (right to	\$189.96	02/07/2022			A		973		(1)		02/02/2031	Comr		973	\$0	973		D		

Explanation of Responses:

1. Each equity is fully vested at the time of grant, but represent equity awards for prior annual meetings in 2019, 2020 and 2021 that the Company was not able to grant. If the grants had been made at the time of the prior annual meetings, each grant would have vested upon the earlier of (1) the 1 year anniversary of the date of grant or (2) the next annual meeting.

Remarks:

/s/ William Solis, as Attorneyin-Fact for Xiaoying Mai

02/09/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.